RNA has recently emerged as an important nanotechnology platform due to its extraordinary diversity in structure and function. Small interfering RNA (siRNA), showed significant potential in new molecular approaches to down-regulate specific gene expression in mammalian cells. In fact, targeted gene suppression by antisense DNA and siRNA has shown promising preclinical results, and/or is currently in clinical trials for a variety of diseases, including many forms of cancer (e.g., melanoma, neuroblastoma, and pancreatic adenocarcinoma), genetic disorders, and macular generation . Despite the high therapeutic potential of siRNA, its application for clinical medicine is still limited mainly due to the lack of appropriate delivery systems. In such a situation, the development of clinically suitable, safe, and effective drug-delivery biomaterials are required for the widespread use of siRNA therapeutics for disease treatment. Gene Silencing by siRNA Nanoparticles Synthesized via Sonochemical Method: Shimanovich U, Munder A, Loureiro A, Azoia NG, Gomes A, Cavaco-Paulo A, Gedanken A and Gruzman A. OMICS Group International is one of the leading Open Access Publishers which is publishing 700+ peer-reviewed journals. Each and every article undergoes a peer-review process to assess the quality of the article. Molecular Biology mostly welcomes novel manuscripts with novel ideas for the welfare of the human race. Generally, these publications appreciate articles those that are accessible even to those people who are not specialist in the field but are interested in those research topic. These journals are periodical publications that are intended to share the progress of science.
Last date updated on April, 2024